Biogen is a Cambridge, Massachusetts biopharmaceutical company that develops and sells medicines for neurology and rare diseases. It last closed at $249.59 on Nov 20, up 1.00% on the day. The next earnings report for BIIB is expected around Tue, Jan 12, 2027, after the close. For the quarter ended Sep 2026, BIIB reported EPS of -$0.14 on revenue of $2.80B, with revenue up 10.6% from a year ago. Over its last 8 reports the stock moved an average of 2.9% the session after earnings. Over the last 12 months BIIB insiders bought $585 of stock on the open market and sold $905K, according to SEC Form 4 filings.
AI Auto Pilots
Is BIIB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BIIB.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on BIIBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
BIIB · as of the Nov 20 close · updated each morning
Uptrend
The stock sits between its 20 and 50 day averages. It is 17% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the Pivot S1 at $247.42, and the nearest resistance the Pivot at $250.21.
Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 2.9%/day
Key levels
$261.0052 week high+4.6%
$254.41Swing high (Oct 22)+1.9%
$252.38Pivot R1+1.1%
$250.6520 day average+0.4%
$250.21Pivot+0.2%
$249.59Last close
$247.42Pivot S1−0.9%
$243.03Swing low (Oct 28)−2.6%
$236.8350 day average−5.1%
$223.15100 day average−10.6%
$206.87200 day average−17.1%
$160.3652 week low−35.8%
Indicators
RSI (14)
54.05
Middle of its range
Neutral
MACD
3.62
Below its signal line
Bearish
Stochastic
44.6
Middle of its range
Neutral
ADX (14)
22.6
Weak trend
Williams %R
-54.3
Oversold below −80, overbought above −20
Neutral
CCI (20)
-28.7
Oversold below −100, overbought above 100
Neutral
Rate of change
+0.5%
Change over 10 sessions
Bullish
ATR (14)
$7.20
Typical daily range, 2.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend, nearing overbought
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 5.7%/day
Key levels
$261.0052 week high+4.6%
$254.41Swing high (Oct 22)+1.9%
$252.38Pivot R1+1.1%
$250.6520 day average+0.4%
$250.21Pivot+0.2%
$249.59Last close
$247.42Pivot S1−0.9%
$243.03Swing low (Oct 28)−2.6%
$236.8350 day average−5.1%
$223.15100 day average−10.6%
$206.87200 day average−17.1%
$160.3652 week low−35.8%
Indicators
RSI (14)
68.68
Strong, overbought above 70
Neutral
MACD
14.89
Above its signal line
Bullish
Stochastic
82.8
Near the top of its range
Overbought
ADX (14)
35.8
Trending up
Williams %R
-21.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
122.9
Oversold below −100, overbought above 100
Overbought
Rate of change
+14.9%
Change over 10 sessions
Bullish
ATR (14)
$14.12
Typical daily range, 5.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for BIIB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BIIB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow BIIB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for BIIBHow many large options trades hit BIIB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in BIIB in the last 90 days.
From SEC Form 4 filings by BIIB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.
From the company's 10-Q filed Oct 28, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BIIB is in one of them and how their past BIIB trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Biogen
Biogen is a biopharmaceutical company based in Cambridge, Massachusetts. It discovers, develops and sells medicines for serious and complex diseases, with a focus on neurology, specialized immunology and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and ALS, along with biosimilars of widely used biologic drugs. Its customers include patients and healthcare providers, and it also works with partners such as Eisai and Genentech on other medicines.